A Rare Presentation of Metastatic Renal Cell Carcinoma Masquerading as Vitritis: A Case Report and Review of Literature

A Rare Presentation of Metastatic Renal Cell Carcinoma Masquerading as Vitritis: A Case Report and Review of Literature

We report a case of a 74-year-old gentleman who presented with floaters and decreased vision in the right eye after cataract surgery. His past medical history was significant for metastatic renal cell carcinoma (mRCC) to bone, lung and abdomen which was presumed stable for the last two years while o...

Full description

Bibliographic Details
Main Authors:	Maria Del Valle Estopinal, Robert T. Swan, Kevin Rosenberg
Format:	Article
Language:	English
Published:	MDPI AG 2022-07-01
Series:	Diagnostics
Subjects:	metastatic renal cell carcinoma vitritis tyrosine kinase inhibitor retinal vasculitis
Online Access:	https://www.mdpi.com/2075-4418/12/7/1712

Similar Items

Primary ovarian adenocarcinoma presenting with rubeotic glaucoma and vitritis: A case report
by: Nakhleh Abu‐Yaghi, et al.
Published: (2022-04-01)

Diagnostic difficulties in a very rare case of mycoplasma pneumoniae uveitis
by: Hadad Ana-Maria-Catalina, et al.
Published: (2023-09-01)

The role of sunitinib in the therapy of metastatic renal cell carcinoma
by: I. G. Rusakov, et al.
Published: (2020-07-01)

Targeted Therapy for Renal Cell Carcinoma: a Prospective study
by: Robin Joshi, et al.
Published: (2015-06-01)

Metastatic esophageal carcinoma to the eye masquerading as inflammatory vitreo-retinitis: A case report and literature review
by: Reham Shehada, et al.
Published: (2023-01-01)

Pazopanib as first-line therapy for patients with metastatic kidney cancer
by: B. Ya. Alekseev, et al.
Published: (2018-07-01)

First-Line Treatments and Management of Metastatic Renal Cell Carcinoma Patients: An Italian Interdisciplinary Uro-Oncologic Group Algorithm
by: Francesco Bloise, et al.
Published: (2024-06-01)

A case of metastatic renal cell carcinoma successfully treated with deferred cytoreductive nephrectomy following lenvatinib plus pembrolizumab combination therapy
by: Hiroaki Sato, et al.
Published: (2023-05-01)

Comparing efficacy and safety of first-line treatment of metastatic renal cell carcinoma: A Bayesian network meta-regression analysis
by: Suyang Qin, et al.
Published: (2023-02-01)

Therapies in Refractory Metastatic Renal Cell Carcinoma
by: Stephanie Berg, et al.
Published: (2022-11-01)

Micro-RNAs Predict Response to Systemic Treatments in Metastatic Renal Cell Carcinoma Patients: Results from a Systematic Review of the Literature
by: Martina Monti, et al.
Published: (2022-05-01)

Dynamic Changes in Serum Immunoglobulin G Predict Clinical Response and Prognosis in Metastatic Clear-cell Renal Cell Carcinoma
by: Honglei Cui, et al.
Published: (2024-12-01)

A case of hyperammonemia occurring during treatment of metastatic renal cell carcinoma with axitinib
by: Shoichi Kimura, et al.
Published: (2023-07-01)

Differential cellular effects of sunitinib and pazopanib targeted drugs for metastatic renal cell carcinoma
by: Filipa Amaro, et al.
Published: (2022-04-01)

Does the Timing of Cytoreductive Nephrectomy Impact Outcomes? Analysis of REMARCC Registry Data for Patients Receiving Tyrosine Kinase Inhibitor Versus Immune Checkpoint Inhibitor Therapy
by: Margaret F. Meagher, et al.
Published: (2024-05-01)

Adverse Events of Cabozantinib as a Potential Prognostic Factor in Metastatic Renal Cell Carcinoma Patients: Real-World Experience in a Single-Center Retrospective Study
by: Piotr Domański, et al.
Published: (2024-02-01)

Targeted Therapy Following Metastasectomy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-analysis
by: Hui Mo Gu, et al.
Published: (2024-03-01)

Current Options for Second-Line Systemic Therapy in Metastatic Renal Cell Carcinoma
by: Iraklis C. Mitsogiannis, et al.
Published: (2022-09-01)

TARGET THERAPY IN PATIENTS OF LIVER METASTATIC CANCER PATIENTS IN REAL CLINICAL PRACTICE
by: B. Y. ALEXEEV, et al.
Published: (2016-12-01)

Comparison of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma with rhabdoid and sarcomatoid differentiations
by: Kun Wang, et al.
Published: (2023-07-01)

Estimated cost of VEGFR TKI associated adverse events in metastatic renal cell carcinoma patients
by: Jeffrey Thomas Yorio, et al.
Published: (2024-10-01)

Lenvatinib Monotherapy Versus Lenvatinib in Combination with PD-1 Blockades as Re-Challenging Treatment for Patients with Metastatic Osteosarcoma: A Real-World Study
by: Song G, et al.
Published: (2025-02-01)

Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score
by: Giulia Mazzaschi, et al.
Published: (2023-07-01)

Renal cell carcinoma with multiple bone metastases effectively treated by a combination of tyrosine kinase inhibitor, robot‐assisted partial nephrectomy, and metastasectomy
by: Atsuro Sawada, et al.
Published: (2024-03-01)

La Toxoplasmosis ocular.
by: Daniel Leiva Rojas, et al.
Published: (2022-08-01)

Bilateral rhegmatogenous retinal detachments in a patient taking pazopanib: A case report
by: Nolan J. Adams, et al.
Published: (2022-06-01)

Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet‐Uro 19BEYOND study
by: Giandomenico Roviello, et al.
Published: (2022-08-01)

Metastatic renal cell carcinoma, the possibility of targeted therapy. Case.
by: K. V. Menshikov, et al.
Published: (2021-12-01)

Development and validation of a nomogram to evaluate the therapeutic effects of second-line axitinib in patients with metastatic renal cell carcinoma
by: Dengqiang Lin, et al.
Published: (2023-02-01)

Feasibility Study on Using Dynamic Contrast Enhanced MRI to Assess the Effect of Tyrosine Kinase Inhibitor Therapy within the STAR Trial of Metastatic Renal Cell Cancer
by: Jim Zhong, et al.
Published: (2021-07-01)

A Meta-Analysis to Assess the Efficacy of HER2-Targeted Treatment Regimens in HER2-Positive Metastatic Colorectal Cancer (mCRC)
by: Akshit Chitkara, et al.
Published: (2023-09-01)

Impressive and Prolonged Response with Lenvatinib in a Highly Pretreated Patient with Metastatic Clear Cell Renal Cancer: A Case Report
by: Sara Demurtas, et al.
Published: (2024-04-01)

Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis
by: Kinga Krawczyk, et al.
Published: (2023-09-01)

Real-world short-term outcomes and treatment regimen comparisons in patients with metastatic renal cell carcinoma treated with first-line immune combinations
by: Masato Kikuta, et al.
Published: (2025-01-01)

Treatment of metastatic renal cell carcinoma to the brain: a report of long-term survival following multimodal treatment and sequential use of targeted agents
by: Chih-Chin Yu, et al.
Published: (2014-12-01)

Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma
by: Christopher Kwok, et al.
Published: (2023-07-01)

Metastatic mesenchymal chondrosarcoma showing a sustained response to cabozantinib: A case report
by: Veronika Blum, et al.
Published: (2022-12-01)

Unusual fractured dexamethasone implant in the vitreous cavity
by: Jui Telavane, et al.
Published: (2024-01-01)

Recurrent ocular toxoplasmosis infection in a patient with a selective deficiency of NK T-cells and cytotoxic СD8+ T-cells associated with a genetic folate cycle deficiency
by: D. V. Maltsev, et al.
Published: (2022-08-01)

Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma—A network meta-analysis. Focus on cabozantinib combined with nivolumab
by: Maciej Niewada, et al.
Published: (2023-03-01)